Glycinorm Total 30 Tablet SR is a combination oral antidiabetic medication containing Gliclazide (30 mg), Pioglitazone (15 mg), and Metformin (500 mg), formulated for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Gliclazide, a sulfonylurea derivative, enhances insulin secretion from pancreatic beta cells, thereby reducing blood glucose levels. Pioglitazone, a thiazolidinedione class agent, improves insulin sensitivity in peripheral tissues by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), promoting glucose uptake and utilization. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral glucose uptake, contributing to overall glycemic regulation. The combined pharmacological actions of these agents provide complementary mechanisms to effectively control hyperglycemia, reduce insulin resistance, and improve metabolic parameters. Glycinorm Total 30 Tablet SR is indicated for patients inadequately controlled on monotherapy or dual therapy, offering a convenient once-daily dosing regimen due to its sustained-release formulation. It should be used under medical supervision with regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and fluid retention. This combination therapy supports comprehensive management of type 2 diabetes, aiming to reduce the risk of diabetes-related complications.